SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: pz who wrote (775)8/16/1999 9:04:00 PM
From: Mad2  Read Replies (2) | Respond to of 5582
 
Dan and Howard
The following appeared in Gum's release
''We are pleased with our continued progress in increasing net sales
on a year-to-year basis. Sales of Zicam(TM) were as expected. As noted at the end of
the last reporting period, we anticipate that increasing sales of Zicam(TM) will start to be
reflected in the third quarter.''
Key statement is Zicam sales were as expected. Someone should ask GUMM mgmt what they expect in the 3rd and 4th qtr, given their smug confidence on "hitting the numbers" and given many a investor in GUMM is counting on Zicam to justify the stock price.
GUMM investors should ask mgmt to share their projections with them (revenue and operating profit) and lend objectivity to the share ownership issue, otherwise unrealstic expectations drive price and opportunistic "insiders" are the benificaries.
Best Regards,
Mad2



To: pz who wrote (775)8/17/1999 11:36:00 AM
From: JDN  Read Replies (2) | Respond to of 5582
 
Dear pz: Sales of Zicam were "AS EXPECTED???". Seems to me a lousy $100,000 is NOT much to expect. I find it hard to believe they have all the outlets they say they have and such small sales. Maybe its all SAMPLES. JDN


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News